Didn’t last as usual

From March. The last paragraph is beyond bizarre considering what is known publicly:

LOS ANGELES, CA / March 6, 2024 / Pacific Ventures Group, Inc. (OTC PINK:PACV) (“Pacific Ventures” or the “Company”), a food and beverage holding company specializing in the distribution of consumer food, beverage and alcohol-related products, today announced that, in furtherance of the success of its ongoing balance sheet restructuring, the Company has completed payments on its long-standing debt obligation to BNA Investment Capital, LLC and TRA Capital, LLC.

“We are excited and proud to have paid off what started out as a $400,000 debt to BNA and TRA, and it reinforces our commitment to, and the success of, our ongoing balance sheet restructuring efforts,” stated Shannon Masjedi, President and CEO of Pacific Group Ventures.The fully repaid obligation to BNA Investment Capital and TRA Capital relates to a settlement agreement that arose from litigation that began in 2020.

“Our recent successes in restructuring our balance sheet have begun to yield increased cash flow available for our operations, which, we are convinced, will place our operating subsidiaries in a more favorable posture for increasing sales.” This further prepares and aligns with the Company’s goal of moving to a higher trading platform in the near future.

Same for me for quite some time now. As far as I know no one has gotten a response recently.

318K shares for sell at eleven cents. Right about my cost average. Prefer to sell all to one investor if possible. This is a modest chunck of my holdings. It is actually in an account I set up for my son a long time ago. Since I had to retire quite early due to health problems from Covid-19, I need to raise money to get him through college.

VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) --

Dear Shareholders,

I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering support.

Fiscal year 2024 was a significant year for CytoDyn, and one that I believe will be remembered as the beginning of a turnaround. The Company achieved the lifting of the FDA’s clinical hold in late February 2024 and is now working to return to the clinic. Over the past several months, the Company has made significant internal progress on key initiatives which we believe will lead to marked external developments in the form of the commencement of clinical trials, the rollout of a number of pre-clinical research initiatives, and the continued publication of leronlimab data.

Shortly after my appointment as the Company’s CEO in November 2023, I hosted an investment update at which I committed to prioritizing the following: (i) getting off clinical hold, which required the submission of a revised trial protocol to the FDA; (ii) publishing clinical data that had not yet been released; and (iii) exploring how to extend leronlimab’s platform wherever it made sense. As I reflect on my first six months as CEO, I am pleased with the progress, but our work is not yet done.

Over the next six months, we expect to commence at least one, and potentially two clinical trials. The prospective clinical trials, in order of priority, are: (i) a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer; and (ii) a Phase II study exploring leronlimab’s effects on inflammation. The Company’s priority will be the oncology trial which, if successful, will put us on track towards a commercial approval of leronlimab in that indication. The inflammation study is aimed at clarifying certain provocative observations related to leronlimab, and to help define the dose and underlying mechanism of anti-inflammatory action. It is imperative that the Company generate unassailable results in the clinic and I believe the above trials can accomplish this. Starting the oncology study and related fundraising is the top priority of the Company at this time, but our current hope is that we can initiate both studies before the end of this calendar year.

Research and development partnership opportunities are important to the Company as we search for cost-effective ways to further build out our product development portfolio. We have identified several such opportunities that we believe are intriguing, and anticipate finalizing agreements with these partners in the very near future. Such potential partnerships include an investigator-initiated pilot study of leronlimab in patients with Alzheimer’s Disease, and a project that will evaluate the use of leronlimab in patients living with HIV who are undergoing stem cell transplantation in a proof of cure study. Following lifting of the clinical hold, we have observed a significant increase in third parties that are interested in partnering with the Company. We will continue to review opportunities as they arise, given the potential for significant value return at little or no cost to the Company.

Finally, as promised, CytoDyn has submitted several leronlimab manuscripts for peer review and is in the process of completing final drafts of several others. The clinical endpoint data from the Long COVID trial (CD 15) was recently published in the Journal of Infection. All publications will be available on the Company’s website soon after publication.

I believe the Company is building for success and has made significant strides toward initiating a number of key pre-clinical and clinical leronlimab trials. I am also pleased to share that things are progressing well as to the development of a longer-acting therapeutic with our partner who utilizes its proprietary artificial intelligence platform.

As shareholders, you are the lifeblood of the Company and we remain committed to acting in your best interests. Your questions and feedback are always appreciated. Included herewith is a copy of the May 2024 “Frequently Asked Questions” supplement. This FAQ supplement is something that is also posted on the Company’s website and updated from time to time. You are always welcome to submit questions to the Company’s IR email account: ir@cytodyn.com.

I understand that the Company’s historical challenges may have tested your confidence, and I am grateful for your ongoing support and trust. My dedication to the Company is founded in my belief that leronlimab has the potential to be a life-changing therapeutic. As always, our commitment is to bring better healthcare to patients in need, and to maximize shareholder value.

Sincerely,

Dr. Jay Lalezari
CEO

Given the debt problem wake alerts us about and the current share price something has to give. Lack of management providing clear communication to current shareholders is disturbing. No way I'd get involved as a potential new buyer. Shannon and company have given no reason to think they can turn this around yet.

A month later and still nothing from CRXM.

Item 1.02 Termination of Material Definitive Agreement.

On April 3, 2024, CytoDyn Inc. (the “Company”) and Samsung BioLogics Co., Ltd. (“Samsung”) executed an agreement (the “Letter Agreement”), wherein the parties reached agreement for an orderly process for winding down services and a restructuring of the amount payable by the Company to Samsung (the “Total Balance”). The Letter Agreement resolves the Company’s obligations under the Master Services Agreement and related ancillary agreements first entered into between Samsung and the Company in or around April 2019 (collectively, the “Agreement”).

The Total Balance due as restructured under the Letter Agreement is $43,821,231.32. Except for a single $250,000 payment due on or before December 31, 2024, the entirety of the Total Balance is contingent, and will only be due and payable, upon the Company achieving a qualifying “Revenue” event, as defined in the Letter Agreement. Under the Letter Agreement, the Company agreed to pay 20% of its qualifying Revenue generated in each calendar year, if any, with such payments to be applied to reduce the Total Balance until it is repaid in full. Interest will not accrue on the Total Balance throughout the prospective repayment period. Revenue is defined in the Letter Agreement as:

“…the gross revenue generated by Client and its Affiliates, less the following items (if not previously deducted from the amount invoiced): (a) reasonable and customary trade, quantity, and cash discounts actually granted and legally permitted wholesaler chargebacks actually paid or credited by Client and its Affiliates to wholesalers of products; (b) reasonable, customary, and legally permitted rebates and retroactive price reductions actually granted; (c) freight charges for the delivery of products; (d) the portion of the administrative fees paid during the relevant time period to group purchasing organizations, pharmaceutical benefit managers and/or government-mandated Medicare or Medicaid Prescription Drug Plans relating specifically to the product; and (e) sales, use or excise taxes imposed and actually paid in connection with the sale of products (but excluding any value added taxes or taxes based on income or gross receipts).”

As part of the wind down process under the Letter Agreement, at the discretion of the Company, Samsung will arrange for the shipment of specified drug product, substance and reference standards previously manufactured and/or utilized by Samsung to a storage facility selected by the Company. Any vials and/or batches of drug substance and drug product the Company elects not to ship and store at an alternate vendor will be destroyed.

Under the original Agreement between the parties, Samsung performed non-exclusive services relating to technology transfer, process validation, manufacturing, pre-approval inspection, vial filling, and supply and storage services for leronlimab bulk drug substance and drug product. Samsung was one of several companies the Company engaged for such services. The Company believes it currently has enough drug product and substance to complete its contemplated clinical activity and will be transitioning the aforementioned services to one, or several, of its current service providers.

https://archive.fast-edgar.com/20240401/AW2ZQ22CZC2RA2T2222D22Y2HRVSZZ22QV62/

Late filing notice out per usual.

Thanks JJ24 for reaching him and reporting here. Did he provide anything about how he was going about buying back the company?

Additionally, whoever is funding the buyout beyond Chris, what is their interest in getting the company back to being current in the SEC fikings and trading which is going to have a significant cost. Or do they plan on not being a public traded company?

Then there is the several million dollars needed to fund the trial.

Any idea if CRXM responded to the order?

They have let the website sevices go to shit. Not that they would have posted the info anyway. That would show at least some responsibility on their part to keep investors informed.

https://genebiotherapeutics.com/press/

https://genebiotherapeutics.com/investors/

The lack of communication is astonishing. WTF is the plan besides touting oneself as the the most respected woman in meat Shannon?

I saw that. Interesting that is equal to the rest of the days trading volume.

I sent yet another email to Shannon this AM. No answer. Big surprise.

...and the price of PACVD shares are going in the shitter

Good question. Most likely answer is money. I'm sure it's going to take hundreds of thousands to get current.

If Nostrum isn't able to provide financial support then what good are they? My expectattion was they could fund the trial directly or had resources to get the financing. Perhaps no lender will work with them given their situation. Enough time has passed I'd hoped Chris would have found a way to move things along without Nostrum.

No one seems to know anything based on the lack of comments.

Anyone reached out to CRXM management about this?

I got that via the PACV news email. It isn't showing on my Schwab SSE trading platform news alert for whatever reason.

LOS ANGELES, CA / March 6, 2024 / Pacific Ventures Group, Inc. (OTC PINK:PACV) (“Pacific Ventures” or the “Company”), a food and beverage holding company specializing in the distribution of consumer food, beverage and alcohol-related products, today announced that, in furtherance of the success of its ongoing balance sheet restructuring, the Company has completed payments on its long-standing debt obligation to BNA Investment Capital, LLC and TRA Capital, LLC.

“We are excited and proud to have paid off what started out as a $400,000 debt to BNA and TRA, and it reinforces our commitment to, and the success of, our ongoing balance sheet restructuring efforts,” stated Shannon Masjedi, President and CEO of Pacific Group Ventures.The fully repaid obligation to BNA Investment Capital and TRA Capital relates to a settlement agreement that arose from litigation that began in 2020.

“Our recent successes in restructuring our balance sheet have begun to yield increased cash flow available for our operations, which, we are convinced, will place our operating subsidiaries in a more favorable posture for increasing sales.” This further prepares and aligns with the Company’s goal of moving to a higher trading platform in the near future.

Another month has gone by with nothing from the company. Silence sucks.

Guess the split designation is coming off in a day or two. Time to bait new gullible investors after that happens?

Product aside, company can't be taken seriously at this time based on past actions by Shannon and Marc.

Yeah, it is hard to see the path forward right now for stock considering her and Marc's lack of leadership.

How long can someone fail before realizing they need to bring in help?

I wonder what the current situation with Nostrum is with their interest and financial means to move things forward.

Made it through the first month of a new year with no news since the Dec 4th info about the online platform being operational.

Three months ago this was his position. I am curious if anything has changed:

Altitrade Partners

Re: bentleyt post# 6073

Tuesday, October 24, 2023 10:27:41 AM

Post#
6074
of 6111
What makes you feel so confident?

- A strong belief in GeneRx drug therapy and CEO Chris Reinhard's ability to get it to the market.

What do you honestly see for the future of CRXM

- Sorry, our crystal ball is currently in the shop for repair.

What is your anticipated timeframe?

- As long as it takes

I'm kind of curious myself.

My take on CR is he's a pretty bright guy and means well. I question whether he has the skillset to raise funds at this point to move research forward. Clearly he put all of his, and our eggs in the Nostrum basket. Now that Nostrum is in a bad way, what is the work around?

One would think Mr Grainer would have the know how and contacts to make this happen but here we sit almost three years since the last meaningful news release and nearly 2 years since the last filing.

Websites are up as I just checked.

Welcome to the board. Best of luck to you.

Hard to believe Shannon and Marc settled the debt with shares without a plan in place to move things forward. What happens when people stop buying shares. I wonder if PACV even cares what happens to the stock anymore.

The thing that bothers me is Nostrum has been under financial pressure for going on a couple years now. If they had helped with the funding early on we would be at the end of the trial by now and potentially have a big pharma partner or have been bought out. This would have put Nostrum in a much stronger financial position as well as shareholders.

I have no doubt Chris Reinhard has known about these issues for quite some time and nothing has changed. As far as I know he has not publicly communicated with shareholders in a very long time. I know several have reached out with little or no success.

For Pete's sake, our COB/CFO is Nostrum's CFO (as far as I know). How can this not be handled more optimally given such tight control?

A New Year is here. Nostrum knows their punishment from the Feds. It is time for them to figure out the plan AND inform CRXM shareholders.

I'm not sure Nostrum Pharma or Nostrum Lab exists anymore. Website links do not work for me. Could be they are rebranding I suppose. Either way Gene Bio is probably low on their to do list funding wise.

You may be correct about Gene Bio's ability to move things ahead. That was the whole idea about bringing in the pharma group. But I doubt Chris Reinhard expected Nostrum to have this happen which I just found using Google:

https://www.justice.gov/opa/pr/drugmaker-nostrum-and-its-ceo-agree-pay-50-million-settle-false-claims-act-claims

Probably right but you never know what might happen. My question is who is buying these shares? Perhaps they know something you and I don't.

Anyone have experience in being an activist investor and getting put on the BOD of a public company to help a company move ahead?

I know we have a couple 5% +/- shareholders. Perhaps one might be interested in being our Carl Icahn or Bill Ackman.

Neither the CEO, the COB nor the SEC are willing to comment on whether Sabby/Mintz were shorting CRXM. I've asked.

Nearly 3 years since this was released. How about a end of year/new year update????

https://pacvgroup.com/pacific-ventures-group-provides-strategic-plan-and-synergies-for-its-recent-acquisition-of-seaport-meat-company/

8K
https://archive.fast-edgar.com/20231221/AJ2Z322CZZ2RRTPN229T2ZY2AUQRZZ22ZB52/